Attaching Sugar Molecules to Somatostatin Makes It Last Longer and Work Better as a Drug
Adding human complex-type sugar chains to somatostatin analogs made them metabolically stable while maintaining high binding affinity to all five somatostatin receptor subtypes — something existing somatostatin drugs cannot achieve.
Quick Facts
What This Study Found
Chemical glycosylation of somatostatin analogs with human complex-type N-glycans (oligosaccharides) achieved two goals simultaneously:
1. Metabolic stability — the glycosylated analogs resisted the rapid plasma degradation that limits native somatostatin's clinical use
2. Broad receptor affinity — the analogs maintained high binding affinity to all five somatostatin receptor subtypes (sst1-5)
This is notable because existing somatostatin drugs (like octreotide and lanreotide) sacrifice broad receptor coverage for stability — they are metabolically stable but only bind strongly to sst2 and sst5. The glycosylated analogs achieve both properties. The authors conclude that chemical glycosylation is a powerful general strategy for improving peptide and protein drug candidates.
Key Numbers
How They Did This
The researchers synthesized somatostatin analogs and chemically attached human complex-type oligosaccharides (N-glycans) to them. The glycosylated analogs were assessed for metabolic stability (resistance to plasma degradation) and binding affinity to all five somatostatin receptor subtypes (sst1-5). Pharmacokinetic profiles were evaluated to determine improved drug properties compared to native somatostatin.
Why This Research Matters
Current somatostatin analogs like octreotide (used for acromegaly, carcinoid tumors, and other conditions) only target a subset of somatostatin receptors. Many diseases involve multiple receptor subtypes, meaning current drugs miss part of the therapeutic effect. A stable analog that activates all five receptors could be more effective for conditions where multiple receptor subtypes contribute — and could open entirely new therapeutic indications. The glycosylation approach could also be applied to improve many other peptide drugs.
The Bigger Picture
Glycosylation — adding sugar chains to proteins — is nature's own strategy for extending protein half-life and modulating function (most antibodies are glycosylated). Applying this to small peptides is a newer approach that competes with other half-life extension strategies like PEGylation (adding polyethylene glycol) and fatty acid attachment (used in semaglutide). If glycosylation can consistently improve peptide drugs without compromising activity, it could become a standard tool in the peptide drug developer's toolkit.
What This Study Doesn't Tell Us
The abstract does not provide specific quantitative data on binding affinities, half-life extension, or pharmacokinetic parameters. No in vivo efficacy studies in disease models are described — only drug property characterization. The complexity of synthesizing glycosylated peptides at scale could be a manufacturing challenge. Whether the broad receptor profile translates to clinical advantages over existing selective analogs remains to be demonstrated. No safety or toxicity data are mentioned.
Questions This Raises
- ?Would glycosylated somatostatin analogs show superior efficacy over octreotide or lanreotide in diseases where multiple sst receptors are involved?
- ?Can the chemical glycosylation approach be scaled to pharmaceutical manufacturing, or is it limited to research quantities?
- ?Could this glycosylation strategy be applied to other short-lived therapeutic peptides like GLP-1, oxytocin, or vasopressin?
Trust & Context
- Key Stat:
- All 5 receptor subtypes retained Unlike current somatostatin drugs that lose affinity for most receptors when modified for stability, glycosylated analogs maintained high binding to all sst1-5 subtypes
- Evidence Grade:
- This is a drug chemistry study demonstrating improved properties of glycosylated peptide analogs. While the approach is promising, only in vitro binding and stability data are described — no disease model efficacy or clinical data are presented. The evidence is at the early preclinical stage.
- Study Age:
- Published in 2023, this study represents a current approach in the active field of peptide drug optimization. Chemical glycosylation as a half-life extension strategy is still emerging relative to more established methods.
- Original Title:
- Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug Properties.
- Published In:
- Chemistry (Weinheim an der Bergstrasse, Germany), 29(31), e202300111 (2023)
- Authors:
- Ochiai, Hirofumi, Shimoda, Taiji, Fukae, Kazuhiro, Maeda, Masatoshi, Ishii, Kazuyuki, Yoshida, Kenta, Tezuka, Katsunari, Tazuru, Keisuke, Saijo, Hayato, Asai, Hiroaki, Kanatani, Akio, Nishiuchi, Yuji
- Database ID:
- RPEP-07235
Evidence Hierarchy
Frequently Asked Questions
What is somatostatin and what is it used for?
Somatostatin is a peptide hormone (14 or 28 amino acids) that acts as a natural 'brake' on many body functions — it inhibits growth hormone, insulin, glucagon, and digestive secretions. Synthetic versions (octreotide, lanreotide) are used to treat conditions like acromegaly (excess growth hormone), carcinoid tumors, and severe diarrhea. The problem with natural somatostatin is that it breaks down in the blood within minutes.
How does adding sugar molecules make peptides work better as drugs?
Sugar chains (glycans) are bulky, water-loving molecules that shield peptides from the enzymes that would normally break them down in the blood. They also increase the peptide's size, slowing its filtration through the kidneys. Together, these effects dramatically extend how long the peptide stays active in the body. The key innovation here is that they used human-type sugars, which the immune system recognizes as 'self,' reducing the risk of immune reactions.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07235APA
Ochiai, Hirofumi; Shimoda, Taiji; Fukae, Kazuhiro; Maeda, Masatoshi; Ishii, Kazuyuki; Yoshida, Kenta; Tezuka, Katsunari; Tazuru, Keisuke; Saijo, Hayato; Asai, Hiroaki; Kanatani, Akio; Nishiuchi, Yuji. (2023). Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug Properties.. Chemistry (Weinheim an der Bergstrasse, Germany), 29(31), e202300111. https://doi.org/10.1002/chem.202300111
MLA
Ochiai, Hirofumi, et al. "Better Peptides via Chemical Glycosylation: Somatostatin Analogues Having a Human Complex-Type N-Glycan with Improved Drug Properties.." Chemistry (Weinheim an der Bergstrasse, 2023. https://doi.org/10.1002/chem.202300111
RethinkPeptides
RethinkPeptides Research Database. "Better Peptides via Chemical Glycosylation: Somatostatin Ana..." RPEP-07235. Retrieved from https://rethinkpeptides.com/research/ochiai-2023-better-peptides-via-chemical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.